Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,881 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Renal Diseases Clear all
Completed No phase listed Observational

Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease

NCT02142101
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phosphate Intake's Effect on the Skeletal System - Pilot

NCT00187629
View directory record Official record
Conditions
Healthy, Kidney Failure, Chronic
Interventions
dietary phosphorus
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 19, 2026, 4:21 AM EDT
Completed No phase listed Observational

Live Kidney Donor Study

NCT00608283
View directory record Official record
Conditions
Kidney Transplantation, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT07083557
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions
Endothelial cell collection
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Bone in CKD Alkali Response (BICARb Pilot Trial)

NCT05918029
View directory record Official record
Conditions
Chronic Kidney Diseases, Bone Loss
Interventions
Potassium Citrate Extended Release Oral Tablet, Placebo, Potassium Citrate and Citric Acid Oral Solution
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
5 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
The Bronx, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

NCT05879302
View directory record Official record
Conditions
End Stage Renal Disease, End-Stage Kidney Disease, Kidney Transplantation, Esrd
Interventions
Kidney Offer Shared Decision Making
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Intradialytic Drug Removal by Short-daily Hemodialysis

NCT00596167
View directory record Official record
Conditions
End Stage Renal Disease, Infection
Interventions
Intravenous antibiotics
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 19, 2026, 4:21 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Applications of MRI in Kidney Disease

NCT02832505
View directory record Official record
Conditions
Chronic Kidney Disease, End-stage Kidney Disease
Interventions
No intervention but only observational
Other
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Completed No phase listed Observational Results available

HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis

NCT01343251
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Not listed
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Not applicable Interventional

Safety Study of the Aethlon Hemopurifier

NCT02215902
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C Infection
Interventions
Affinity plasmapheresis
Device
Lead sponsor
Aethlon Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Managing Chronic Kidney Disease in Eastern North Carolina

NCT01054066
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Chronic Kidney Disease Education
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Volume,Sodium and Blood Pressure Management in HD

NCT01766882
View directory record Official record
Conditions
End Stage Renal Failure
Interventions
Lower sodium intervention, Progressive Challenge to Post Dialysis Weight
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Advance Care Planning in the Emergency Department

NCT05209880
View directory record Official record
Conditions
Congestive Heart Failure, Metastatic Cancer, Chronic Kidney Disease Requiring Chronic Dialysis, Chronic Obstructive Pulmonary Disease
Interventions
ED GOAL
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

NCT00054483
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
bortezomib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

NCT00077610
View directory record Official record
Conditions
Anemia
Interventions
Epoetin alfa or beta, RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY2928057 in Hemodialysis Participants

NCT01991483
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Kidney Disease, Chronic
Interventions
LY2928057, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Resistance Training During Maintenance Dialysis

NCT00363961
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Resistance exercise
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 4 Interventional Results available

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

NCT03781089
View directory record Official record
Conditions
Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer Oral Powder Product
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional

SPYRAL GEMINI Pilot Study

NCT06907147
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions
Multi-Organ Denervation Gemini System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Stanford, California • Orlando, Florida • Safety Harbor, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT00448708
View directory record Official record
Conditions
Kidney Diseases, ESRD
Interventions
Vascular Wrap Paclitaxel-Eluting Mesh, Lifespan® ePTFE Vascular Graft
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Fresno, California • Inglewood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02865850
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
54
States / cities
Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

NCT03036150
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
55
States / cities
Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

NCT04365218
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MEDI8367, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 19, 2026, 4:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™

NCT03095391
View directory record Official record
Conditions
Kidney Diseases, Renal Insufficiency, Chronic, Acute Kidney Injury, Urologic Diseases, Renal Insufficiency
Interventions
VFI, Iohexol
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Birmingham, Alabama • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 19, 2026, 4:21 AM EDT